NASDAQ:SURFSurface Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Surface Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.89 +0.20 (+4.26 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$4.62Now: $4.89▼$5.2650-Day Range$1.79MA: $3.00▼$5.9552-Week Range$1.15Now: $4.89▼$7.66Volume1.33 million shsAverage Volume5.65 million shsMarket Capitalization$138.48 millionP/E RatioN/ADividend YieldN/ABeta2.09 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Surface Oncology. Previous Next 2.6 Community Rank Outperform VotesSurface Oncology has received 146 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSurface Oncology has received 133 “underperform” votes. (Add your “underperform” vote.)Community SentimentSurface Oncology has received 52.33% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote “Outperform” if you believe SURF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSurface Oncology does not currently pay a dividend.Dividend GrowthSurface Oncology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surface Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 33.00% of the stock of Surface Oncology is held by insiders.Percentage Held by Institutions48.24% of the stock of Surface Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Surface Oncology are expected to decrease in the coming year, from ($0.96) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surface Oncology is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surface Oncology is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurface Oncology has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.72 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SURF Previous Symbol CUSIPN/A CIKN/A Webwww.surfaceoncology.com Phone617-714-4096Debt Debt-to-Equity Ratio0.43 Current Ratio6.97 Quick Ratio6.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.36 million Price / Sales9.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book1.70Profitability EPS (Most Recent Fiscal Year)($1.97) Net Income$-54,790,000.00 Net Margins-70.90% Return on Equity-38.44% Return on Assets-20.13%Miscellaneous Employees76 Outstanding Shares28,320,000Market Cap$138.48 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:SURF Rates by TradingView Receive SURF News and Ratings via Email Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter. Surface Oncology (NASDAQ:SURF) Frequently Asked Questions How has Surface Oncology's stock been impacted by COVID-19 (Coronavirus)? Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SURF stock has increased by 106.3% and is now trading at $4.89. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Surface Oncology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Surface Oncology. When is Surface Oncology's next earnings date? Surface Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Surface Oncology. How were Surface Oncology's earnings last quarter? Surface Oncology Inc (NASDAQ:SURF) released its quarterly earnings results on Tuesday, May, 12th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.31. The firm had revenue of $38.59 million for the quarter, compared to analyst estimates of $38.59 million. Surface Oncology had a negative net margin of 70.90% and a negative return on equity of 38.44%. View Surface Oncology's earnings history. Has Surface Oncology been receiving favorable news coverage? News stories about SURF stock have trended very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Surface Oncology earned a coverage optimism score of -3.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutSurface Oncology. Are investors shorting Surface Oncology? Surface Oncology saw a drop in short interest in May. As of May 15th, there was short interest totaling 97,700 shares, a drop of 27.0% from the April 30th total of 133,800 shares. Based on an average daily trading volume, of 121,000 shares, the short-interest ratio is currently 0.8 days. Approximately 0.7% of the shares of the company are short sold. View Surface Oncology's Current Options Chain. Who are some of Surface Oncology's key competitors? Some companies that are related to Surface Oncology include Rubius Therapeutics (RUBY), DBV TECHNOLOGIE/S (DBVT), Autolus Therapeutics (AUTL), Voyager Therapeutics (VYGR), Agenus (AGEN), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Eiger Biopharmaceuticals (EIGR), CASI Pharmaceuticals (CASI), Tcr2 Therapeutics (TCRR), Verona Pharma (TARA), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA), Gritstone Oncology (GRTS) and Sutro Biopharma (STRO). View all competitors. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Allena Pharmaceuticals (ALNA), Verizon Communications (VZ), Enterprise Products Partners (EPD), Alteryx (AYX), Netflix (NFLX), Vertex Pharmaceuticals (VRTX), Xilinx (XLNX), Carnival (CCL), Enphase Energy (ENPH) and Pfizer (PFE). Who are Surface Oncology's key executives? Surface Oncology's management team includes the following people: Mr. Daniel S. Lynch, Exec. Chairman (Age 61)Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)Dr. Robert W. Ross, Chief Medical Officer (Age 45)Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47) When did Surface Oncology IPO? (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO. What is Surface Oncology's stock symbol? Surface Oncology trades on the NASDAQ under the ticker symbol "SURF." Who are Surface Oncology's major shareholders? Surface Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (2.40%), Victory Capital Management Inc. (2.40%), BlackRock Inc. (0.75%), Acadian Asset Management LLC (0.48%) and Squarepoint Ops LLC (0.05%). View institutional ownership trends for Surface Oncology. Which institutional investors are selling Surface Oncology stock? SURF stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, and BlackRock Inc.. View insider buying and selling activity for Surface Oncology. Which institutional investors are buying Surface Oncology stock? SURF stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., and Acadian Asset Management LLC. View insider buying and selling activity for Surface Oncology. How do I buy shares of Surface Oncology? Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Surface Oncology's stock price today? One share of SURF stock can currently be purchased for approximately $4.89. How big of a company is Surface Oncology? Surface Oncology has a market capitalization of $138.48 million and generates $15.36 million in revenue each year. The company earns $-54,790,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Surface Oncology employs 76 workers across the globe. What is Surface Oncology's official website? The official website for Surface Oncology is www.surfaceoncology.com. How can I contact Surface Oncology? Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
